Title:Vernodalin Triggers ROS-Mediated Apoptosis in TPC-1 Human Papillary
Thyroid Cancer Cells via Suppression of the MAPKs Signaling Pathway
Volume: 27
Issue: 14
Author(s): Xijia Yang, Meng Wei, Yuan An, Qinlong Liang, Jing Nan, Annamalai Vijayalakshmi and Zizhang Wang*
Affiliation:
- Department of Head and
Neck Surgery, Shaanxi Provincial Tumor Hospital, The Affiliated Hospital of Xi'an Jiaotong Univesity, Xi’an, 710061, P.R.
China
Keywords:
Thyroid cancer, papillary thyroid cancer, vernodalin, apoptosis, MAPKs, DCFH staining method.
Abstract:
Background: Thyroid Cancer (TC) is an endocrine organ malignancy that has become
more common in recent decades. Vernodalin (VN), a cytotoxic sesquiterpene, has been reported
to exhibit anticancer properties against human breast and liver cancer cells. However, no study
has explored the efficacy of VN with respect to its antiproliferative and apoptotic action on human
Papillary Thyroid Cancer cells (PTC).
Objective: The study intended to examine the antitumor and antiproliferative effects of VN and
the apoptosis mechanisms underlying its action on TPC-1 human PTC cells.
Methods: In this study, we examined the VN cell viability by MTT assay; performed ROS
measurement by DCFH staining method, MMP identification by Rh-123 staining method, and
apoptotic morphological assay by employing AO/EB and DAPI stain method, and further, p38
MAPK/ERK/JNK cell proliferation markers were determined by western blotting technique.
Results: The findings showed that VN could inhibit the growth of PTC cells by increasing intracellular
ROS, damaging MMP, and stimulating apoptosis in a concentration-dependent manner.
The study demonstrated how VN inhibited TPC-1 cell viability by causing ROS-induced cell
death via the MAPK signaling pathway.
Conclusion: VN may serve as an agonist to impact apoptosis in PTC cells. In human PTC, VN
could play an effective role in chemotherapy. More studies pertaining to animal tumor models
are needed to prove its anti-cancer effectiveness in vivo.
